Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Translation Initiation Research.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for EIF4A2 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | EIF4A2 Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View EIF4A2 Products |
| Gene Delivery | EIF4A2 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View EIF4A2 Products |
| Benchmark Ab | Anti-EIF4A2 Recombinant Antibody Recombinant positive control. |
View EIF4A2 Products |
| Validator | EIF4A2 siRNA Set For knockdown verification. |
View EIF4A2 Products |
| Related Target A | EIF4A1 Highly homologous translation initiation factor; essential for selectivity and counter-screening panels. |
View EIF4A1 Products |
| Related Target B | EIF4E Key component of the eIF4F translation initiation complex; synergistic target in oncogenic translation inhibition. |
View EIF4E Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Distinguishing EIF4A2 from EIF4A1 (~90% homology) | Human EIF4A1 and EIF4A2 ortholog proteins available with >95% purity for parallel SPR/BLI selectivity profiling. |
| Assaying ATPase / RNA helicase activity without host contamination | Ultra-pure recombinant proteins strictly verified by mass spectrometry to exclude bacterial ATPase contamination. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) and sequence-verified positive controls included. |
| False Positives in Knockdown Studies | Validated siRNA sets included for target-specific knockdown and phenotypic verification. |
Live EIF4A2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for EIF4A2 therapeutics is intensifying, with major players shifting focus from traditional global translation inhibitors to selective small-molecule modulators and chemical inducers of dimerization (CIDs). As first-generation therapies targeting the eIF4F complex reach clinical trials, the next wave of R&D is targeting highly selective EIF4A2 inhibition to limit systemic toxicity associated with pan-eIF4A inhibition.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (Rocaglates / CIDs) | eFFECTOR Therapeutics, Academic Institutions | Solid Tumors (NSCLC, Breast Cancer), Colorectal Cancer | RNA-clamping & ATP-hydrolysis assays (Need highly purified, sequence-verified EIF4A2 and EIF4A1) |
| Antisense Oligonucleotides / RNAi | Preclinical Biotechs | Hematological Malignancies, Viral Infections | Target knockdown validation (Need sequence-verified siRNA / Lentivirus) |
| Small Molecule (Allosteric Inhibitors) | Pharmaceutical Innovators | Drug-Resistant Cancers | Selectivity assays against homologous helicases (Need EIF4A1/EIF4A2 panel screening) |